Friday, Cephalon, Inc. (CEPH) announced that its wholly-owned subsidiary, Cephalon International Holdings, Inc., intends to make about A$318 million or US$207 million takeover offer for Arana Therapeutics Limited (AAH.AX).
Under its bid, Cephalon intends to offer A$1.40 cash for each Arana ordinary share cum dividends and other rights. The offer price represents a 70% premium to Arana's 90-day volume weighted average price and a 69% premium to the closing price on February 25, 2009, the last trading day before the announcement.
Cephalon already has acquired a shareholding in Arana, representing an ownership position of approximately 19.9% of the total issued share capital of Arana. The purchase price of the shares was A$1.40 per share.
Cephalon noted that if it obtains a relevant interest in 90% of Arana shares and the offer conditions are satisfied or waived, Cephalon will increase its offer price by 5 Australian cents per share. In these circumstances accepting Arana shareholders will receive A$1.45 per share. Cephalon said it intends to fund the offer price using a portion of its existing cash balance.
Arana independent directors, who support the offer, will recommend it to Arana shareholders in the absence of a superior proposal.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.